Table 5. Association of Lp-PLA2 with MI and total stroke (including later events).
VariablesHR (95% CI) by quartile of Lp-PLA2P for trend
Q1Q2Q3Q4
MI (776 cases/1992 subcohort)
    Lp-PLA2 activity
        Adjusted for age and race/ethnicity1.001.25 (0.96–1.64)1.37 (1.05–1.79)2.06 (1.60–2.66)<0.0001
        Fully adjusteda1.001.20 (0.90–1.61)1.08 (0.80–1.48)1.40 (1.00–1.95)0.084
    Lp-PLA2 mass
        Adjusted for age and race/ethnicity1.001.04 (0.79–1.35)1.32 (1.02–1.72)1.72 (1.34–2.20)<0.0001
        Fully adjusted1.001.09 (0.81–1.47)1.33 (0.99–1.79)1.61 (1.19–2.18)0.0006
Stroke (952 cases/1992 subcohort)
    Lp-PLA2 activity
        Adjusted for age and race/ethnicity1.001.24 (0.98–1.56)1.11 (0.88–1.41)1.24 (0.98–1.56)0.19
        Fully adjusted1.001.24 (0.96–1.61)0.93 (0.71–1.23)0.88 (0.64–1.20)0.13
    Lp-PLA2 mass
        Adjusted for age and race/ethnicity1.001.18 (0.92–1.52)1.59 (1.24–2.03)1.89 (1.49–2.39)<0.0001
        Fully adjusted1.001.43 (1.09–1.88)1.81 (1.38–2.39)2.32 (1.75–3.07)<0.0001
  • a Fully adjusted, adjusted for age, race/ethnicity, prior diabetes, angina, statin use, current smoking, the natural logs of SBP, total and HDL cholesterol and CRP, family history of premature MI, and Hb A1c among diabetic patients. Models were additionally adjusted for current and past use of hormone therapy as appropriate.